Caris Life Sciences^® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. The Caris Molecular Tumor Board Report is an innovative research-use-only (RUO) tumor profiling report that provides an additional tumor biology resource and is available upon request when ordering MI Cancer Seek^®.

The Caris AI Insights section of the Caris Molecular Tumor Board Report includes signatures powered by artificial intelligence, including proprietary Caris signatures. These signatures leverage Caris' clinico-genomic data in predicting therapy response, identifying tissue of origin, assessing metastasis risk and guiding personalized treatment strategies for each patient.

Caris recently added the breast cancer signature for capecitabine to the Caris AI Insights section of the Caris Molecular Tumor Board Report. The signature utilizes more than 2,000 expression and copy number features from a patient's Whole Exome and Whole Transcriptome profile to predict response to capecitabine for first-line chemotherapy in HER2-negative breast cancer patients. Capecitabine is an oral chemotherapy drug used to treat breast cancer, among other cancers.

"Molecular profiling is a vital step in gaining a comprehensive understanding of a patient's cancer," said Caris President David Spetzler, MS, PhD, MBA. "Caris AI Insights help researchers and clinicians provide a valuable molecular blueprint of a patient's tumor biology and is another way Caris' testing goes above and beyond for patients, clinicians and researchers."

Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.